Lytix Biopharma As
Clinical trials sponsored by Lytix Biopharma As, explained in plain language.
-
Experimental combo shows promise in rare sarcoma trial
Disease control CompletedThis study tested a two-step treatment for people with advanced soft tissue sarcoma that had stopped responding to standard therapy. First, a drug called LTX-315 was injected into a tumor to attract immune cells. Then, that tumor was removed, and the immune cells were grown in a …
Phase: PHASE2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated May 02, 2026 23:05 UTC
-
New combo therapy shows promise for hard-to-treat melanoma
Disease control CompletedThis study tested a new drug combination for people with advanced melanoma that no longer responds to standard immunotherapy. The treatment involves injecting a drug called LTX-315 directly into tumors along with an intravenous immunotherapy drug, pembrolizumab. The goal was to s…
Phase: PHASE2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated May 01, 2026 15:58 UTC